Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haleon plc is a consumer healthcare company. The Company’s product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

  • Revenue in GBP (TTM)11.30bn
  • Net income in GBP1.05bn
  • Incorporated2021
  • Employees24.00k
  • Location
    Haleon PLCBuilding 5, First Floor, The HeightsBRENTFORD KT13 0NYUnited KingdomGBR
  • Phone+44 193 282 2000
  • Websitehttps://www.haleon.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HLN:LSE since
announced
Transaction
value
System Two US IncDeal completed01 Apr 202301 Apr 2023Deal completed3.42%--
Data delayed at least 20 minutes, as of Mar 28 2024 09:24 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genmab A/S1.89bn499.95m15.83bn2.20k31.554.31--8.3666.0566.05249.95483.850.5037--3.097,474,592.0013.3117.4314.2518.5955.82--26.4235.8713.32--0.0238--13.5740.35-20.1824.21-4.66--
argenx SE970.32m-233.46m18.71bn1.15k--5.76--19.28-4.75-4.7519.8763.940.31950.43733.72986,714.40-7.69-17.65-8.49-19.7990.39---24.06-97.729.01--0.0049--198.56117.2558.42--122.32--
UCB SA4.50bn293.82m18.95bn9.08k64.612.4021.404.211.761.7626.9147.300.33451.764.63578,223.102.185.032.676.2867.5072.216.5312.660.92243.140.252936.44-4.802.54-18.33-15.41-1.512.36
Bayer AG40.81bn-2.52bn23.92bn99.72k--0.8483.740.5861-2.99-2.9948.4933.520.39511.434.85477,693.20-2.44-1.79-3.34-2.3858.5459.02-6.18-4.800.80153.400.5764---6.115.33-170.87--1.19-47.66
HALEON PLC11.30bn1.05bn30.14bn24.00k29.241.8449.082.670.11280.11281.221.800.32823.155.76470,916.703.23--3.73--61.59--9.83--0.73497.370.3611--4.09---1.04------
Lonza Group AG5.88bn572.51m34.90bn17.90k60.294.0929.275.948.888.8890.98130.870.39282.804.84--3.835.074.646.2129.0039.149.7514.521.2012.350.227530.587.943.92-46.17-0.030623.957.78
Data as of Mar 28 2024. Currency figures normalised to Haleon PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.20%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 2023205.96m2.23%
The Vanguard Group, Inc.as of 07 Mar 2024204.52m2.22%
Norges Bank Investment Managementas of 31 Dec 2023125.64m1.36%
MFS International (UK) Ltd.as of 29 Feb 2024124.35m1.35%
First Eagle Investment Management LLCas of 31 Jan 2024117.36m1.27%
BlackRock Investment Management (UK) Ltd.as of 29 Feb 202497.66m1.06%
BlackRock Fund Advisorsas of 07 Mar 202492.01m1.00%
Harding Loevner LPas of 31 Dec 202385.13m0.92%
Franklin Mutual Advisers LLCas of 31 Dec 202384.90m0.92%
BlackRock Advisors (UK) Ltd.as of 06 Mar 202481.09m0.88%
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.